{"pmid":32378044,"pmcid":"PMC7201114","title":"Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients: comment.","text":["Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients: comment.","Intern Emerg Med","Roncon, Loris","Zuin, Marco","Rigatelli, Gianluca","32378044"],"journal":"Intern Emerg Med","authors":["Roncon, Loris","Zuin, Marco","Rigatelli, Gianluca"],"date":"2020-05-08T11:00:00Z","year":2020,"_id":"32378044","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1007/s11739-020-02358-4","keywords":["covid-19","heparin","treatment"],"e_drugs":["Heparin"],"topics":["Treatment"],"weight":1,"_version_":1666262687609257984,"score":9.490897,"similar":[{"pmid":32440985,"title":"Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients: comment.","text":["Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients: comment.","Intern Emerg Med","Allione, Attilio","Giamello, Jacopo Davide","Paglietta, Giulia","Bernardi, Sara","Cavalot, Giulia","32440985"],"journal":"Intern Emerg Med","authors":["Allione, Attilio","Giamello, Jacopo Davide","Paglietta, Giulia","Bernardi, Sara","Cavalot, Giulia"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32440985","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1007/s11739-020-02373-5","e_drugs":["Heparin"],"topics":["Treatment"],"weight":1,"_version_":1667523504850862080,"score":145.4611},{"pmid":32297089,"pmcid":"PMC7157827","title":"Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients.","text":["Switch from oral anticoagulants to parenteral heparin in SARS-CoV-2 hospitalized patients.","The development of COVID-19 syndrome in anticoagulated patients, and especially their admission to intensive-care units with acute severe respiratory syndrome (SARS-CoV-2), expose them to specific problems related to their therapy, in addition to those associated with the acute viral infection. Patients on VKA hospitalized with SARS-CoV-2 show high instability of PT INR due to the variability of vitamin K metabolism, diet, fasting, co-medications, liver impairment, and heart failure. Patients on DOAC are exposed to under/over treatment caused by significant pharmacological interferences. In consideration of the pharmacological characteristics of oral anticoagulant drugs, the multiple pharmacological interactions due to the treatment of acute disease and the possible necessity of mechanical ventilation with hospitalization in intensive-care units, we suggest replacing oral anticoagulant therapies (VKA and DOAC) with parenteral heparin to avoid the risk of over/under treatment.","Intern Emerg Med","Testa, Sophie","Paoletti, Oriana","Giorgi-Pierfranceschi, Matteo","Pan, Angelo","32297089"],"abstract":["The development of COVID-19 syndrome in anticoagulated patients, and especially their admission to intensive-care units with acute severe respiratory syndrome (SARS-CoV-2), expose them to specific problems related to their therapy, in addition to those associated with the acute viral infection. Patients on VKA hospitalized with SARS-CoV-2 show high instability of PT INR due to the variability of vitamin K metabolism, diet, fasting, co-medications, liver impairment, and heart failure. Patients on DOAC are exposed to under/over treatment caused by significant pharmacological interferences. In consideration of the pharmacological characteristics of oral anticoagulant drugs, the multiple pharmacological interactions due to the treatment of acute disease and the possible necessity of mechanical ventilation with hospitalization in intensive-care units, we suggest replacing oral anticoagulant therapies (VKA and DOAC) with parenteral heparin to avoid the risk of over/under treatment."],"journal":"Intern Emerg Med","authors":["Testa, Sophie","Paoletti, Oriana","Giorgi-Pierfranceschi, Matteo","Pan, Angelo"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32297089","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1007/s11739-020-02331-1","keywords":["covid-19","doac","lmwh","sars-cov-2","vka"],"e_drugs":["Vitamin K","Heparin"],"topics":["Treatment"],"weight":1,"_version_":1666138493291593728,"score":140.01024},{"pmid":32476080,"title":"The association between treatment with heparin and survival in patients with Covid-19.","text":["The association between treatment with heparin and survival in patients with Covid-19.","This study investigates the association between the treatment with heparin and mortality in patients admitted with Covid-19. Routinely recorded, clinical data, up to the 24th of April 2020, from the 2075 patients with Covid-19, admitted in 17 hospitals in Spain between the 1st of March and the 20th of April 2020 were used. The following variables were extracted for this study: age, gender, temperature, and saturation of oxygen on admission, treatment with heparin, hydroxychloroquine, azithromycin, steroids, tocilizumab, a combination of lopinavir with ritonavir, and oseltamivir, together with data on mortality. Multivariable logistic regression models were used to investigate the associations. At the time of collecting the data, 301 patients had died, 1447 had been discharged home from the hospitals, 201 were still admitted, and 126 had been transferred to hospitals not included in the study. Median follow up time was 8 (IQR 5-12) days. Heparin had been used in 1734 patients. Heparin was associated with lower mortality when the model was adjusted for age and gender, with OR (95% CI) 0.55 (0.37-0.82) p = 0.003. This association remained significant when saturation of oxygen < 90%, and temperature > 37 degrees C were added to de model with OR 0.54 (0.36-0.82) p = 0.003, and also when all the other drugs were included as covariates OR 0.42 (0.26-0.66) p < 0.001. The association between heparin and lower mortality observed in this study can be acknowledged by clinicians in hospitals and in the community. Randomized controlled trials to assess the causal effects of heparin in different therapeutic regimes are required.","J Thromb Thrombolysis","Ayerbe, Luis","Risco, Carlos","Ayis, Salma","32476080"],"abstract":["This study investigates the association between the treatment with heparin and mortality in patients admitted with Covid-19. Routinely recorded, clinical data, up to the 24th of April 2020, from the 2075 patients with Covid-19, admitted in 17 hospitals in Spain between the 1st of March and the 20th of April 2020 were used. The following variables were extracted for this study: age, gender, temperature, and saturation of oxygen on admission, treatment with heparin, hydroxychloroquine, azithromycin, steroids, tocilizumab, a combination of lopinavir with ritonavir, and oseltamivir, together with data on mortality. Multivariable logistic regression models were used to investigate the associations. At the time of collecting the data, 301 patients had died, 1447 had been discharged home from the hospitals, 201 were still admitted, and 126 had been transferred to hospitals not included in the study. Median follow up time was 8 (IQR 5-12) days. Heparin had been used in 1734 patients. Heparin was associated with lower mortality when the model was adjusted for age and gender, with OR (95% CI) 0.55 (0.37-0.82) p = 0.003. This association remained significant when saturation of oxygen < 90%, and temperature > 37 degrees C were added to de model with OR 0.54 (0.36-0.82) p = 0.003, and also when all the other drugs were included as covariates OR 0.42 (0.26-0.66) p < 0.001. The association between heparin and lower mortality observed in this study can be acknowledged by clinicians in hospitals and in the community. Randomized controlled trials to assess the causal effects of heparin in different therapeutic regimes are required."],"journal":"J Thromb Thrombolysis","authors":["Ayerbe, Luis","Risco, Carlos","Ayis, Salma"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32476080","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1007/s11239-020-02162-z","keywords":["coronavirus infections","covid-19","heparin","mortality","pulmonary embolism","thrombosis"],"locations":["Spain","heparin","clinicians"],"countries":["Spain"],"countries_codes":["ESP|Spain"],"topics":["Treatment"],"weight":1,"_version_":1668437835170971648,"score":74.8808},{"pmid":32445064,"title":"Heparin resistance in COVID-19 patients in the intensive care unit.","text":["Heparin resistance in COVID-19 patients in the intensive care unit.","Patients with COVID-19 have a coagulopathy and high thrombotic risk. In a cohort of 69 intensive care unit (ICU) patients we investigated for evidence of heparin resistance in those that have received therapeutic anticoagulation. 15 of the patients have received therapeutic anticoagulation with either unfractionated heparin (UFH) or low molecular weight heparin (LMWH), of which full information was available on 14 patients. Heparin resistance to UFH was documented in 8/10 (80%) patients and sub-optimal peak anti-Xa following therapeutic LMWH in 5/5 (100%) patients where this was measured (some patients received both anticoagulants sequentially). Spiking plasma from 12 COVID-19 ICU patient samples demonstrated decreased in-vitro recovery of anti-Xa compared to normal pooled plasma. In conclusion, we have found evidence of heparin resistance in critically unwell COVID-19 patients. Further studies investigating this are required to determine the optimal thromboprophylaxis in COVID-19 and management of thrombotic episodes.","J Thromb Thrombolysis","White, D","MacDonald, S","Bull, T","Hayman, M","de Monteverde-Robb, R","Sapsford, D","Lavinio, A","Varley, J","Johnston, A","Besser, M","Thomas, W","32445064"],"abstract":["Patients with COVID-19 have a coagulopathy and high thrombotic risk. In a cohort of 69 intensive care unit (ICU) patients we investigated for evidence of heparin resistance in those that have received therapeutic anticoagulation. 15 of the patients have received therapeutic anticoagulation with either unfractionated heparin (UFH) or low molecular weight heparin (LMWH), of which full information was available on 14 patients. Heparin resistance to UFH was documented in 8/10 (80%) patients and sub-optimal peak anti-Xa following therapeutic LMWH in 5/5 (100%) patients where this was measured (some patients received both anticoagulants sequentially). Spiking plasma from 12 COVID-19 ICU patient samples demonstrated decreased in-vitro recovery of anti-Xa compared to normal pooled plasma. In conclusion, we have found evidence of heparin resistance in critically unwell COVID-19 patients. Further studies investigating this are required to determine the optimal thromboprophylaxis in COVID-19 and management of thrombotic episodes."],"journal":"J Thromb Thrombolysis","authors":["White, D","MacDonald, S","Bull, T","Hayman, M","de Monteverde-Robb, R","Sapsford, D","Lavinio, A","Varley, J","Johnston, A","Besser, M","Thomas, W"],"date":"2020-05-24T11:00:00Z","year":2020,"_id":"32445064","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1007/s11239-020-02145-0","keywords":["covid-19","heparin","intensive care","thrombosis"],"locations":["optimal","thromboprophylaxis"],"e_drugs":["Heparin, Low-Molecular-Weight","Heparin"],"topics":["Treatment"],"weight":1,"_version_":1667600475927609344,"score":73.32852},{"pmid":32470198,"title":"Clinical differentiation of anticoagulant and non-anticoagulant properties of heparin.","text":["Clinical differentiation of anticoagulant and non-anticoagulant properties of heparin.","I thank Lindahl and Li for their thoughtful comments on the non-anticoagulant properties of heparin.(1) Heightened awareness of hypercoagulability has made heparin part and parcel of the COVID-19 management algorithms. In addition, reports of prophylactic anticoagulation failure have triggered several trials where escalated doses of heparin are compared with standard doses with the aim of preventing thrombotic complications. At this juncture, we do need to consider where do the non-anticoagulant properties of heparin fit in the COVID-19 clinical context?","J Thromb Haemost","Thachil, Jecko","32470198"],"abstract":["I thank Lindahl and Li for their thoughtful comments on the non-anticoagulant properties of heparin.(1) Heightened awareness of hypercoagulability has made heparin part and parcel of the COVID-19 management algorithms. In addition, reports of prophylactic anticoagulation failure have triggered several trials where escalated doses of heparin are compared with standard doses with the aim of preventing thrombotic complications. At this juncture, we do need to consider where do the non-anticoagulant properties of heparin fit in the COVID-19 clinical context?"],"journal":"J Thromb Haemost","authors":["Thachil, Jecko"],"date":"2020-05-30T11:00:00Z","year":2020,"_id":"32470198","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/jth.14933","topics":["Treatment"],"weight":1,"_version_":1668167110008766464,"score":64.896515}]}